Vision Benefits: What Employers Offer, What Members Use, and Whether It Belongs in the Plan

Vision benefits are high take up, low cost, and analytically thinner than dental. The standard employer sponsored vision plan covers an annual exam and a hardware allowance. The question is whether vision belongs inside the plan architecture at all or whether it functions as a standalone voluntary benefit. The answer depends on whether the employer views vision as a hardware subsidy or as an integrated screening component, because retinal examination can detect diabetes, hypertension, and neurological conditions before they present as medical claims.

What Vision Benefits Cost and What Members Use

#

The standard employer sponsored vision plan provides an annual comprehensive eye exam, a hardware allowance ($130 to $200 for frames), a contact lens allowance, and discounts on lens upgrades such as progressive lenses and anti reflective coatings. Cost runs $5 to $15 per member per month depending on plan richness and group size. VSP and EyeMed dominate the employer sponsored vision market with network pricing and hardware allowances that have become standardized across carriers.

According to the KFF 2024 Employer Health Benefits Survey, 82 percent of employers offering health benefits also offer separate vision coverage, up from 17 percent in 2010. The growth reflects both employee demand and the low cost of adding vision to the benefits package. The 2022 Employee Benefits Survey from the International Foundation of Employee Benefit Plans found that 62 percent of employers offer vision benefits as an employer paid benefit.

Utilization patterns are predictable. Eye exam take up runs between 60 and 75 percent in groups that offer employer sponsored vision coverage. Hardware utilization is nearly universal among those who use the benefit: employees who get an eye exam and need corrective lenses claim the hardware allowance. The benefit design creates this pattern because the hardware allowance is use it or lose it within the plan year.

The economic comparison between bundled, carved out, and voluntary vision is less consequential than the comparable dental analysis because the absolute dollar amounts are smaller. The per member per month differential between models is measured in single digit dollars rather than the double digit range relevant for dental. A 25 person group paying $10 PMPM for carved out vision pays $3,000 annually; bundled vision might run $8 to $12 PMPM depending on the TPA’s vision network, a difference of $600 to $1,200 per year. This is real money but not the scale of variance that drives major benefits architecture decisions.

The Clinical Screening Value

#

The analytical depth that justifies examining vision beyond a cost comparison is the clinical screening function. A comprehensive eye exam with retinal imaging can detect systemic disease before the patient has symptoms.

The American Academy of Ophthalmology notes that comprehensive eye examinations can identify diabetic retinopathy before the patient knows they have diabetes. The AAO Diabetic Retinopathy Preferred Practice Pattern recommends that people with type 2 diabetes should have a prompt screening at the time of diagnosis and at least yearly screenings thereafter, because retinal changes may already be present when diabetes is diagnosed. For type 1 diabetes, annual screenings should begin five years after diagnosis. However, only about 60 percent of people with diabetes receive the recommended yearly screenings for diabetic retinopathy.

Beyond diabetes, retinal examination can detect hypertensive retinopathy before hypertension has been diagnosed or adequately treated. A 2021 study in Ophthalmology Retina using automated retinal image analysis found that among patients screened, human graders identified nine cases of grade 1 to 2 hypertensive retinopathy in patients whose diabetic retinopathy screening was otherwise negative. The retina provides a noninvasive window into systemic vascular health that few other diagnostic approaches can match.

A 2025 systematic review in eClinicalMedicine examined artificial intelligence systems applied to retinal imaging and found that AI models could predict systemic risk factors including hypertension, hyperglycemia, and dyslipidemia with area under the curve values ranging from 0.24 to 0.97. The review noted that the retina is the only physiological window in humans that provides noninvasive visualization of the microvasculature, making it a potential screening tool for evaluating the microvascular status of the kidney and brain. Evidence from prospective cohorts shows that arteriolar narrowing and venular widening predict incident coronary heart disease with pooled adjusted hazard ratios of approximately 1.20.

The International Council of Ophthalmology 2017 guidelines emphasize that tight glycemic and blood pressure control reduce diabetic retinopathy risk and progression, and screening programs must be coupled with access to adequate and timely referral for ophthalmologic care. The practical implication is that a vision benefit that identifies diabetic retinopathy triggers a cascade of care coordination that extends well beyond the eye exam itself.

For a level funded plan, the value proposition shifts when vision is understood this way. The value is not the eye exam or the glasses. It is the early detection of conditions that will become high cost medical claims if they progress unmanaged. A diabetic diagnosed through a retinal screen and managed through primary care produces lower claims than one diagnosed through an emergency department visit for a diabetic crisis. A hypertensive patient identified through retinal examination and started on medication produces lower cardiovascular claims than one who presents with a stroke.

Bundled, Carved Out, or Voluntary

#

The economics favor carved out for most small employers. VSP and EyeMed have purchasing power and provider networks that a TPA bundled vision benefit is unlikely to match. The administrative burden of a separate vision vendor is minimal relative to dental because vision claims volume and complexity are lower. A 25 person group generates perhaps 15 to 20 vision claims per year, compared to potentially 50 or more dental claims. The enrollment process is simple, the claims are routine, and the vendor relationship requires little management attention.

The integration argument for bundled vision is weaker than the corresponding argument for bundled dental. Dental medical claims correlation through periodontal disease and systemic health has robust published evidence from multiple cohort studies and meta analyses. Vision medical correlation through screening is clinically documented but rarely operationalized in employer plan analytics. The TPA that receives a flag from a vision exam detecting diabetic retinopathy and routes the member into a diabetes management program is providing integrated value. The TPA that administers vision alongside medical with no data linkage is not.

Most TPAs do not have the systems in place to receive screening findings from vision exams and act on them. The vision carrier sends a claim for an eye exam. The claim contains a procedure code and a diagnosis code if relevant. It does not contain a structured alert saying “this member showed signs of diabetic retinopathy; recommend diabetes screening.” The data integration that would make vision a meaningful part of the medical plan’s risk stratification does not exist in standard TPA operations. Building that capability requires investment in data infrastructure that most TPAs serving the small group market have not made.

The voluntary option is defensible for employers where cost is the primary constraint. Vision take up remains reasonable even at voluntary pricing because the annual exam and hardware are tangible, used benefits that employees can see and value concretely. A voluntary vision premium of $8 to $12 per month is affordable for most employees who want the benefit, and the adverse selection dynamic is less severe than in dental because vision utilization is more predictable and less driven by deferred care. Employees generally know whether they need glasses, and those who do enroll regardless of employer contribution. The population that opts out of voluntary vision is not deferring expensive care; they simply do not need corrective lenses.

The stop loss treatment of vision claims matters less than stop loss treatment of dental because vision claims rarely reach the scale where they affect aggregate attachment point calculations. A vision claim is an eye exam and a pair of glasses. The claim total might reach $300 to $500. Dental claims can reach thousands of dollars for crowns, root canals, and periodontal treatment. The aggregate risk contribution of vision is negligible in most level funded arrangements.

Closing

#

Vision is a smaller decision than dental with a less obvious integration argument. The clinical screening value is real but unrealized in most plans because the systems to capture and act on screening findings do not exist.

For the 10 person construction company, voluntary vision is the defensible choice. The workforce is younger, the chronic disease prevalence where retinal screening produces clinical value is lower, and the employer’s cost constraint makes voluntary benefits the practical path. Employees who want vision coverage can purchase it at group rates, and those who do not want it incur no cost to the employer.

For the 25 person professional services firm with an older workforce, carved out vision through VSP or EyeMed makes the strongest case. The population includes members in their 40s and 50s who benefit from regular eye exams, and the carved out network provides better provider access than most TPA bundled alternatives. The integration value of bundled vision remains theoretical because the TPA is unlikely to have the systems to act on screening findings.

For the 35 person employer with a TPA that demonstrates dental medical integration capability, bundled vision becomes worth considering. If the TPA can show that it routes members with diabetic retinopathy findings into diabetes management programs, the vision benefit moves from hardware subsidy to clinical tool. This TPA capability is rare but not nonexistent, and the employers who find it should value it.

An employer who views vision as a hardware subsidy should carve it out or offer it as voluntary and move on. An employer who views the annual eye exam as a medical screening opportunity should integrate it with the medical plan and ensure the TPA can act on screening findings. The distinction between these two views is another test of design versus accretion. Most employers will correctly choose carved out vision because the integration value, while theoretically present, requires TPA capabilities that few possess.